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Introduction
Diarrhoeal disease is a major childhood health issue and a 
leading cause of death in children <5 years of age1. Each 
year an estimated 1.73 billion episodes of diarrhoea occur 
worldwide2, and, while there have been reductions in the glo-
bal burden of diarrhoea and diarrhoea-related deaths, the effect 
has been modest in Southeast Asia. In this region, data indi-
cate that each child still experiences 2.4 episodes of diar-
rhoea every year, resulting in 427.4 million cases and 227,700 
deaths annually2. Reasons for disparities in rates of reduction 
are thought to include differences in vaccination implemen-
tation, variation in breast-feeding practices and community-
level case management practices1. Of note, there have been no 
major changes to international diarrhoea treatment algorithms 
over this time period3.
Faecal-oral infection by the Gram-negative bacilli Shigella 
spp. is a leading cause of moderate-to-severe diarrhoea in chil-
dren, particularly in low and middle-income countries4,5. Shig-
ellosis is particularly problematic in Southeast Asia where 
S. sonnei predominates and resistance to antimicrobials has 
reached a critical level6–8. Diarrhoea and dysentery (diarrhoea 
containing blood and/or mucus) due to infection by Shigella 
spp. are known to cause a signiicant burden of disease in 
Vietnam6,9,10, accounting for 49% of hospitalized cases of 
dysentery10. A key concern for the control and management of 
dysentery caused by Shigella spp. and other bacteria in Vietnam 
and elsewhere is the emergence of antimicrobial resistance, 
speciically against luoroquinolones11–13.
Bacterial resistance to luoroquinolones and 3rd generation 
cephalosporins has increased markedly over the last decade in 
Vietnam, in tandem with S. sonnei becoming the predominant 
Shigella species10. Most national and international guidelines 
advocate the antimicrobial treatment of all cases of dysen-
tery in children, due to the high frequency of isolating Shigella 
sp. as the aetiological agent and the high rate of complications 
and death if not treated promptly14,15. In addition to preventing 
death and morbidity, effective treatment reduces shedding and 
transmission14,16. World Health Organization recommendations 
are to use the luoroquinolone, ciproloxacin (CIP), as 1st-line 
treatment and pivmecillinam, ceftriaxone or azithromycin, as 
alternative 2nd-line regimes according to local susceptibil-
ity data15–17. These recommendations were supported by a 2010 
review of historical treatment failures, which estimated a 99% 
cure rate with these antimicrobials18. This high rate of suc-
cess is contradicted by a previous study performed in our set-
ting (Ho Chi Minh City, Vietnam) which suggested an 11% 
clinical failure rate when treating culture-conirmed Shigella 
dysentery cases with CIP19. Since these data were acquired, 
resistance rates have further increased over the last 10 years20. 
Currently, local resistance data suggests Shigella spp. non- 
susceptibility to CIP is ~60% with ~15% of patients failing to 
show a clinical response to treatment and trending upwards 
each year21.
Rationale
With such high rates of resistance in Southeast Asia, there 
may be several direct and indirect beneits to using the 2nd-line 
recommendation, azithromycin (AZI), in preference for the 
treatment of children with dysentery. In addition to its wide-
spread availability and low cost, AZI has a large volume of 
distribution (30L/kg) and a long half-life (70hrs), which results 
in high tissue and intracellular concentrations at concentra-
tions up to 100-fold those in serum22,23. Furthermore, incomplete 
absorption of AZI (low bioavailability; 17–37%) results in high 
concentrations of drug within colonic epithelial cells, which is 
likely to be particularly beneicial in colonic/diarrhoeal infec-
tion. Further theoretical indirect beneits to using AZI for the 
treatment of dysentery may include anti-inlammatory effects 
through IL-1 inhibition or CD4 T-cell suppression24,25. These 
effects may result in a clinical treatment response even in the 
absence of direct in vitro microbicidal activity.
Only two previous randomised controlled trials have evalu-
ated AZI for the treatment of dysentery. The irst, performed in 
Dhaka in 1997, demonstrated that AZI was effective for treat-
ing Shigella dysentery in adult men26. Most cases were caused 
by epidemic S. dysenteriae ST1 strain and rates of multi-drug 
resistance (MDR) and nalidixic acid resistance were high. The 
second study, performed in Paraguay in 2003, demonstrated 
AZI was more effective than ceixime for bacterial eradication 
in children aged 6m – 5yrs, and suggested a trend for bet-
ter clinical outcomes27. Bacterial isolates in this study were 
predominantly S. flexneri (~80%).
Antimicrobial resistance (AMR) is a well-established interna-
tional emergency and children with diarrhoeal infection rep-
resent a signiicant proportion of the total global infectious 
disease burden. With the increasing rates of AMR observed in 
children presenting with dysentery in Vietnam and evidence 
of international transmission events28–30, new data support-
ing alternative treatment options, such as AZI, in particular 
for the new highly-antimicrobial resistant S. sonnei serotype, 
is urgently needed. While antimicrobial resistance to AZI is 
also now not infrequent31, we hypothesize that, due to the dif-
ference in pharmacokinetic/pharmacodynamic characteristics, 
bioavailability and theoretical indirect beneits, AZI may be 
superior treatment for children hospitalised with dysentery in 
Ho Chi Minh City compared to the current standard-of-care, 
CIP.
Objectives and endpoints
The primary objective of our two-group superiority study is 
to measure the eficacy of azithromycin (AZI) compared with 
ciproloxacin (CIP, standard of care) oral antimicrobials for the 
treatment of children hospitalised with dysentery in Ho Chi 
Minh City, Vietnam. The primary endpoint will be the proportion 
of treatment failures detected in each antimicrobial arm of 
the study, as deined by:
•  Clinical treatment failure (fever 38.0°C or the per-
sistence of signs or symptoms of the infection: vom-
iting, abdominal pain, +/-  3 loose stools +/-blood, 
mucus or both) after 120 hours of start of either 
treatment; or
•  Microbiological treatment failure (positive PCR stool 
with original pathogen after completion of treatment 
course) after 72 hours of treatment.
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Secondary objectives include:
1.     Quantify differences in symptom duration between 
treatment groups, stratiied by detection of Shigella spp. 
DNA in stool by PCR.
2.     Assess the time to resolution of objective markers of 
infection and inlammation, including cessation of 
culture- and PCR-conirmed Shigella shedding, nor-
malization of blood total white cell count, C-reactive 
protein and stool lipocalin concentrations.
3.     Assess the rates of adverse events associated with 
exposure to the antimicrobial agents used.
4.     Assess the effects of antimicrobial exposure on the host 
microbiome and resistome, including diversity and 
abundance of bacterial species in stool.
Methods and analysis
Study design
This study is designed as a single centre, open label, rand-
omized controlled trial of two therapeutic options for the anti-
microbial treatment of children hospitalised with dysentery. 
Eligible patients will be randomly assigned to treatment with 
either oral ciproloxacin (15mg/kg/twice daily for 3 days, 
standard-of-care) or oral azithromycin (10mg/kg/daily for 
3 days). Randomisation will be performed by using a set of 
computer-generated random numbers generated by the local 
CTU. Patients will be randomised 1:1 using a variable block 
design with blinding effected by use of identical sealed packs 
containing the allocated treatment generated by the central 
unblinded study pharmacist. Eligible participants will be assigned 
to the next available sequential treatment as recorded in the 
ward enrolment log.
Patient recruitment
Study participants will be recruited from those children aged 6 
to 60 months presenting to Children’s Hospital 2, Ho Chi Minh 
City, Vietnam, with symptoms and signs of dysentery. Chil-
dren’s Hospital 2 is one of three major children’s hospitals in 
the city, it has a 1,400-bed capacity, serving the local commu-
nity and acts as tertiary referral center for children with severe 
infectious diseases and noncommunicable diseases in southern 
Vietnam. After identiication, the admitting paediatric physician 
will approach the child’s parents/guardians to discuss the 
study, to ask them to consider enrolment, and to explain the 
informed consent process. If eligible the attending study 
physician will obtain written informed consent.
Eligibility criteria
Criteria for study inclusion are:
•     Age 6 months to 60 months at time of presentation;
•     Have signs/symptoms of dysentery, speciically passing 
stools containing mucus and/or blood with/without abdominal 
pain, tenesmus or fever (37.8°C);
•     Be within 72 hours of the onset of signs/symptoms;
•     Have a parent/guardian present at admission willing to 
provide written informed consent.
Study exclusion criteria include:
•     Those known to have speciic medical/surgical conditions 
that may affect disease severity/presentation or response 
to treatment (e.g. affecting antimicrobial absorption), 
including: gastrointestinal abnormalities, including short 
bowel syndrome, chronic (inlammatory or irritable) bowel 
disease; inherited or acquired immune system deiciency ren-
dering the patient immunocompromised, including chronic/
long-term steroid treatment or other immunosuppressive 
treatment; patients with known congenital or acquired oste-
oarthropathy, prolongation of the QT interval, congenital long 
QT syndrome;
•     Presentation with severe infection requiring parenteral 
antimicrobial treatment, including shock jaundice, extensive 
gastrointestinal bleeding, convulsion, drowsiness or coma, 
reduced movements on stimulation, tachypnoea >60 times 
per minute, grunting, chest retraction, poor sucking relex;
•     Known hypersensitivity to any of the trial drugs (ciproloxacin 
or azithromycin);
•     Coexisting infection requiring other or additional antimicrobials 
to be prescribed/administered.
Interventions measured
The interventions measured will be ciproloxacin 15mg/kg 
BW/ twice daily, with doses 12 hours apart against azithro-
mycin 10mg/kg BW/once daily and administered by a study 
physician to ensure adherence.
Ciprofloxacin. CIP has a dual-ringed quinolone structure with 
the addition of luorine at position 6 and a piperazinyl group 
at position 7. The bactericidal activity of CIP, which extends 
to Gram negative bacteria, is a result of inhibiting both the 
type II topoisomerase (DNA-gyrase) and type IV topoisomer-
ase enzymes, which are required for bacterial DNA transcrip-
tion, replication, repair and recombination. Inhibition of this 
mechanism results in rapid bacterial cell death.
Quinolone antimicrobials are well absorbed from the gastroin-
testinal system; CIP has an oral bioavailability of 70%. Peak 
concentrations of CIP are reached 1–3 hours after dose inges-
tion with a half-life of 4 hours. While food does not inhibit 
the absorption of quinolone agents, it may result in a delay 
in reaching peak concentrations. Enteral feeding may reduce 
the absorption of quinolone antimicrobials, whether given via 
the oral, nasogastric or jejunal route. CIP has a high volume 
of distribution (VD 231L) penetrating well into most tissues and 
the intracellular macrophage compartment, where concentra-
tions are 2-100x plasma. CIP is eliminated through a combina-
tion of renal and non-renal routes, including intestinal secretion, 
which accounts for 10–15% of drug excretion. Other routes 
of elimination include hepatic metabolism to less active 
forms, which similarly accounts for 10–20% of CIP clearance.
CIP has a broad spectrum of activity, including the Enterobac-
teriaceae, Gram-negative cocci, intracellular atypical pneumo-
nia pathogens and some Gram-positive organisms including 
Mycobacteria and Staphylococci species. Bacterial resistance 
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mechanisms include alterations of the target enzymes or per-
meability mechanisms. CIP resistance by Shigella sonnei, was 
irst reported in 1993 and has been recently been character-
ised as occurring in a single MDR lineage (III) which is now 
dominant globally32. Genome sequencing has identiied that the 
emergence of this globally dominant CIP-resistant strain has 
occurred as a single selection event likely in South East Asia, 
with resistance being acquired sequentially though accumu-
lation of gyrA and parC chromosomal mutations within the 
DNA gyrase and topoisomerase IV genes, respectively. 
Azithromycin. AZI is an azalide antimicrobial related to the 
macrolide erythromycin although with more favourable phar-
macokinetic and side-effects proiles and a broader spectrum 
of activity. Structural differences with erythromycin include 
substitution of nitrogen for a methyl group within the lactone 
ring. This substitution enhances the stability of AZI in acidic 
conditions and thus improves the gastrointestinal absorption and 
bioavailability of the drug. The mechanism of action for AZI 
is similar to other macrolide antimicrobials; inhibition of the 
bacterial 50S ribosomal subunit inhibiting RNA-dependent 
protein synthesis.
The oral bioavailability of AZI is 36% and is further inhibited by 
food (50%), thus administration should be 1 hour before or 2 hours 
after meals. Absorption is also slowed by co-administration 
with magnesium or aluminium-containing antacids. AZI has 
a high volume of distribution (23–31L/kg) and is widely dis-
persed in body tissues including the lung and sputum with 
concentrations reaching 10-100x serum. Very high concen-
trations are found in macrophages and neutrophils, which is 
thought to be due to cellular uptake of the basic compound into 
acidic lysozymes by ionic trapping. AZI has a half-life of 2–4 
days and antibacterial activity may persist for several days 
after completion of a course. Most elimination is of the non- 
metabolised drug via the gallbladder or trans-intestinal route 
into faeces.
AZI has more activity against Gram-negative bacteria in com-
parison to the other macrolides, erythromycin and clarithromy-
cin, but is less active against various Gram-positive organisms 
including Streptococci and Staphylococci. This enhanced activ-
ity is thought to be due to enhanced ability to penetrate the 
Gram-negative cell wall. Resistance to AZI is by alteration of 
the target site (methylation of mRNA nucleotides or mutation 
of ribosomal components, e.g. ermA/B/C), by macrolide modi-
ication (by esterases or phosphotransferases e.g. ereA/B or 
mphA/B/D) or by eflux pump mechanisms (mefA or msrA)33. 
Although sporadically reported to-date, resistance by Shigella 
sp. to AZI is mostly through acquisition of a plasmid carrying 
ermB or mphA genes33–38.
Sample size calculation
In this study, children aged 6 months to 60 months, present-
ing with symptoms of dysentery will be randomised to receive 
antimicrobial treatment with either AZI or CIP. The primary 
endpoint will be clinical or microbiological treatment failure. 
The sample size was based on the eficacy of CIP is 85% 
based on non-clinical response (unpublished data; Duong 
et al. OUCRU Vietnam) and the eficacy of AZI is 95% based on 
non-clinical response (unpublished data; Duong et al. OUCRU 
Vietnam) with type I (Į) errors = 0.05 and 80% of power. We 
need to recruit 140 patients per arm. To account for potential 
inadequacies in our assumptions and some loss to follow-up, 
sample size was increased by 30%. Thus, a total sample size of 
364 participants, 182 in each arm, will be recruited. Parents of 
children meeting the study criteria will be approached daily 
until the participant number has been met. The ward will con-
tain posters and lyers regarding the study and may be expanded 
to other sites if recruitment targets are not met.
Standard-of-care procedures
Aside from the study speciic procedures described, all 
patients admitted to participating wards and enrolled to the study 
will receive standard-of-care treatment according to national 
guidance39. Alterations to the management of each partici-
pant will be at the discretion of the treating physician; whilst in 
hospital, study participants may require additional proce-
dures to be performed to optimise clinical management. In 
cases where the patient is failing to respond to the treatment 
allocated, rescue treatment with an alternative (AZI or third-
generation cephalosporin) will be used. If antimicrobial sus-
ceptibility data becomes available, treatment will be altered as 
required.
Data collection
After enrolment, data will be collected from participants dur-
ing daily review, or if discharged before the inal study 
visit on day 28, on days 3, 7 (+3 days allowable variation), 
and 28 (+3 days). Data sources will include the study partici-
pant and samples collected from them, the study participant’s 
parent(s)/guardian(s) and the clinical care records, including 
but not limited to hospital case notes, imaging, laboratory 
results and nursing/observation record charts.
Comprehensive demographic data will be collected at the 
baseline/day 1 visit including complete previous medical 
and surgical history with participant birthing, breast-feeding 
and immunization record, and details of current and previ-
ous medication use including antimicrobials and visits to 
pharmacies/medicine sellers. Data collected from physical 
examinations performed will include assessment of hydration 
and nutritional status (weight, mean upper arm circumference, 
skin turgor, and mucus membrane moistness) and standard 
physical observations (heart rate, blood pressure, respiratory 
rate, oxygen saturations, and oral temperature measurement). 
Study visits will be performed twice-daily until day 5 with only 
physical observation and adverse event reporting data col-
lected during the afternoon visit (Table 1; afternoon visits not 
shown).
Laboratory methods. Stool specimens will be collected in ster-
ile containers as soon as possible on the day of hospital admis-
sion after informed consent has been obtained. After delivery 
to the laboratory, specimens will be investigated to determine 
a microbiological or parasitological cause for the dysentery 
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episode. In addition, two aliquots of stool sample will be stored 
at -80nC as 10% suspensions in distilled PBS for batched 
viral identiication and secondary analysis.
To examine stool for the presence of parasites, a fresh smear of 
a stool specimen will be prepared in phosphate buffered saline. 
10µL of this solution will be examined at 400x magniication 
and examined for E. histolytica and Giardia lamblia. Fur-
ther examination for Cryptosporidium cysts will be performed 
using Ziehl-Neelsen stain. This procedure will be performed on 
day of admission to the ward only.
Culture methods. All stool specimens will be examined for 
the presence of blood or mucus and cultured for the presence 
of bacterial pathogens. Fresh stool smears of each specimen 
will be examined by x400 microscopy for presence of red/
white blood and pus cells, indicating an inlammatory 
colonic process. Stool cultures will be performed according 
to standard protocols; in brief, specimens will be cultured on 
MacConkey Agar (MC), Xylose-Lysine-Deoxycholate Agar 
(XLD), Selenite broth, and selective Campylobacter media. 
After overnight incubation at 37nC or 48 hours incubation at 
42nC in a micro-aerophilic environment (for Campylobacter 
culture only), identiication of potential pathogens will be per-
formed using standard local protocols incorporating clinical 
mass-spectrometry identiication approaches (Bruker MALDI- 
TOF Biotyper).
Shigella spp. causing dysentery will be identiied through this 
method; primarily as non-lactose fermenting colonies grow-
ing on MC or XLD agar. Speciation will be performed by slide 
agglutination using polyvalent somatic (O) and monovalent 
serotype-speciic antibodies (Denka Seiken, Japan), and con-
irmed by sequencing methods. Susceptibility testing of Shig-
ella spp isolates will be performed using a disc diffusion 
method and by minimum inhibitory concentration antimicro-
bial gradient diffusion, where necessary, on Mueller-Hinton agar 
(Oxoid). Assessment of extended-spectrum B-lactamase phe-
notype organisms will be performed using interpretative read-
ing of the disc diffusion results and with the double-disc 
diffusion synergy test40. Further characterisation of resist-
ance mechanisms will be performed using established in-house 
genotyping methods as appropriate, as previously described11,31.
All isolated pathogens will be stored for future testing and the 
isolated organism will be recorded in the study data. Pathogen 
identiication and relevant susceptibility data will be reported to 
the clinical team as soon as it is available.
Molecular detection methods. To enhance our ability to iden-
tify putative pathogens causing dysenteric symptoms, addi-
tional non-culture-based diagnostics will be performed using 
nucleic acids (DNA or RNA) extracted from stool samples 
collected on the day of hospital admission. Total nucleic acids 
will be extracted from faecal specimens (homogenised and 
diluted 10% in PBS) either using the QIAamp viral RNA 
Mini kit (QIAGEN, Hilden, Germany) or a Roche MagNA 
pure 96 automated nucleic acid extraction machine (Roche). 
After extraction, an aliquot of RNA will be converted to com-
plementary DNA (cDNA) by reverse transcription prior to 
storage at -80ºC until further analysis. Bacterial (and viral) 
pathogen sequences will be detected in stool-extracted cDNA/
DNA by multiplex real-time PCR using established in-house 
protocols41.
Data analysis plan
Source documents are where data are irst recorded, and from 
which participants’ CRF data are obtained. These include, but 
are not limited to, hospital records (from which medical history 
and previous and concurrent medication may be summarised 
Table 1. Visit schedule for the CIPAZ clinical trial.
Visit 1, 
day 0
Visit 3, 
day 1
Visit 5, 
day 3
Visit 7, 
day 4
Visit 9, 
day 5
Visit 11, 
day 710
Visit 12, 
day 2831
Informed consent X
Medical history and physical 
examination
X X X X X X X
Randomization X
Study intervention* X X X
Stool collection X X X X X X X
Laboratory blood tests§ X X
Urine collectionܬܬ X
Adverse event assessment X X X X X X X
*FLSURࢊR[DFLQPJNJ%:WZLFHGDLO\ZLWKGRVHVKRXUVDSDUWRUD]LWKURP\FLQPJNJ%:GDLO\ 2QO\IRUKRVSLWDOLVHG
SDWLHQWVZKRSURGXFHVWRROH[DPLQDWLRQIRURYDF\VWVDQGSDUDVLWHVZLOOEHSHUIRUPHGRQLQLWLDOVWRROVSHFLPHQVRQO\ 6WRRO
VDPSOHRUUHFWDOVZDE§ )XOOEORRGFRXQWDQGELRFKHPLVWU\LQFOXGLQJXUHDFUHDWLQLQHDQGHOHFWURO\WHVOLYHUIXQFWLRQWHVWV
UDQGRPJOXFRVH&UHDFWLYHSURWHLQ&53ܬܬ 6DPSOHIRUWHVWLQJSKHQRW\SLFDQWLPLFURELDODFWLYLW\
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into the CRF), clinical and ofice charts, laboratory and phar-
macy records, and correspondence. CRF entries will be 
considered source data if the CRF is the site of the original 
recording (e.g. there is no other written or electronic record of 
data). All documents will be stored safely in conidential condi-
tions. On all trial-speciic documents, other than the signed con-
sent, the participant will be referred to by the trial participant 
number/code, not by name.
Analysis of the clinical trial data will be performed after data-
set cleaning and not before the inal enrolled participant has 
attended for their Day 3 visit. The primary analysis popula-
tion consists of all participants enrolled and randomised to a 
treatment arm. Outcomes will be analysed according to ran-
domised arm (intention-to-treat population). In addition, the 
primary endpoint will be assessed using the per-protocol pop-
ulation, which will include all participants completing the 
allocated full 3-day antimicrobial course. After data cleaning 
the only people with access to the dataset will be the head of 
the CTU at OUCRU and the trial statistician.
Description of statistical methods. The primary endpoint, the 
proportion of treatment failure (deined by clinical and micro-
biological parameters) by day 28 (+3 days) after enrolment 
will be compared between the study arm (either CIP or AZI) 
based on a logistic regression model with treatment arm is the 
main variable. The primary analysis will not adjust for any cov-
ariates, but in a second step we will also explore the effect of 
the following covariates on the treatment failure (in addition 
to the treatment arm): duration of diarrhoea prior to enrolment, 
age, and pathogen (norovirus, rotavirus, Salmonella spp., Shig-
ella spp., Campylobacter spp., unknown). The secondary end-
points will be compared between the treatment arms based on 
a lognormal accelerated failure time regression model for 
time-to-event endpoints, logistic regression for rate of relapse 
within 7-days (+ 3 days) endpoint.
The primary endpoint, the proportion of treatment failure 
(deined by clinical and microbiological parameters) by day 
28 (+3 days) after enrolment will be compared between study 
arms (either CIP or AZI) by logistic regression modelling 
using treatment allocation as the main variable. The primary 
analysis will not adjust for any covariates, but in a second step 
we will also explore the effect of the following additional cov-
ariates on treatment failure: duration of diarrhoea prior to 
enrolment, age, and pathogen identiied (norovirus, rotavirus, 
Salmonella spp., Shigella spp., Campylobacter spp., unknown). 
The secondary endpoints will be compared between the treat-
ment arms based on a lognormal accelerated failure time 
regression model for time-to-event endpoints and logistic regres-
sion for rate of relapse within the day 7 (+3 days) endpoint.
Ethics and dissemination. This study is sponsored by the 
University of Oxford and will be monitored by the Clinical Tri-
als Unit at the Oxford University Clinical Research Unit, 
Vietnam. The principal investigator (SB) will ensure that this 
study is conducted in accordance with the principles of the 
International Council on Harmonisation Guidelines for Good 
Clinical Practice and amendments42. This protocol and the 
relevant supporting documents have received approval by 
the Oxford Tropical Research Ethics Committee (47–18) and 
the ethical review boards of Children’s Hospital 2 (1341/NĐ2-
CĐT). The study has also been approved by the Vietnamese 
Ministry of Health (5044/QĐ-BYT). The investigators will sub-
mit and, where necessary, obtain approval from the above parties 
for all substantial amendments to the original approved docu-
ments. All trial potential study participant’s parents/guardians will 
provide written informed consent in accordance with the 
Declaration of Helsinki43. SAEs and SARs will be notiied 
to the OUCRU CTU immediately and within no more than 
24 hours of the investigator becoming aware of the event. The 
trial will be audited annulally by the OUCRU CTU audit team.
No information concerning the study or the data will be 
released to any unauthorized third party without prior writ-
ten approval of the sponsor. The study monitor, other authorized 
representatives of the sponsor, representatives of the IRB may 
inspect all documents and records required to be maintained 
by the investigator, including but not limited to, medical 
records (ofice, clinic, or hospital) and pharmacy records for the 
participants in this study. The clinical study site will permit access 
to such records. The study participant’s contact information 
will be securely stored at each clinical site for internal use dur-
ing the study. At the end of the study, all records will continue 
to be kept in a secure location for as long a period as dictated 
by local IRB and Institutional regulations. Study partici-
pant research data, which is for purposes of statistical analy-
sis and scientiic reporting, will be transmitted to and stored 
at the Oxford University Clinical Research Unit, Vietnam (Ho 
Chi Minh City). This will not include the participant’s contact 
or identifying information. Rather, individual participants and 
their research data will be identiied by a unique study iden-
tiication number. The study data entry and study manage-
ment systems used by clinical sites and by OUCRU-Vietnam 
research staff will be secured and password protected. At the 
end of the study, all study databases will be de-identiied and 
archived at OUCRU, Vietnam (Ho Chi Minh City).
Study status
The trial has now received the necessary approvals and recruit-
ment started in November 2019. We anticipate recruitment will 
continue for 18 months and we aim to complete data analysis 
by December 2021.
Dissemination
We will disseminate the results from this study to local and 
regional policy makers to inform updates to current treatment 
guidelines in order to optimise the antimicrobial treatment for 
Shigella dysentery in the new era of widespread antimicrobial 
resistance. We would also aim to present these data at national 
(Vietnam) and international conferences and to report the results 
in open access journals, in keeping with the recommendations 
from the Funder. All people contributing to the protocol and 
downstream analysis will be eligible for inclusion as an author; 
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authorship will be determined by the Principal investigator; 
no professional writers will be sought. Public access to the full 
protocol, participant-level dataset, and statistical code can be 
requested from the Principal investigator.
Data availability
Underlying data
No data is associated with this article.
Extended data
Zenodo: The CIPAZ study protocol: An open label randomised 
controlled trial of azithromycin versus ciproloxacin for the treat-
ment of children hospitalised with dysentery in Ho Chi Minh 
City, Vietnam, http://doi.org/10.5281/zenodo.400456944.
This project contains the following extended data:
-      Full protocol
-      Patient information sheet & informed consent form
Reporting guidelines
Repository name: SPIRIT checklist for ‘The CIPAZ study pro-
tocol: An open label randomised controlled trial of azithromycin 
versus ciproloxacin for the treatment of children hospitalised 
with dysentery in Ho Chi Minh City, Vietnam’, http://doi.
org/10.5281/zenodo.400456944.
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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